| Literature DB >> 22056136 |
Tamra Lysaght1, Alastair V Campbell.
Abstract
The Food and Drug Administration (FDA) has sought an injunction to prevent a US-based company from offering an autologous adult stem cell treatment for musculoskeletal and spinal injuries. Given the alarming number of clinics promoting stem-cell-based interventions, the outcome of this case could have wide-ranging implications. Copyright ÂEntities:
Mesh：
Year: 2011 PMID： 22056136 DOI： 10.1016/j.stem.2011.09.013
Source DB: PubMed Journal: Cell Stem Cell ISSN： 1875-9777 Impact factor: 24.633